novo nordisk glp-1 weight loss Eli Lilly set to leapfrog in weight-loss drug race US FDA says lowest dose

While challenges with adherence, side effects, and weight regain upon discontinuation have prompted the search for additional strategies, targets like GLP-1R, GIPR, and GDF8 (Myostatin) still remain the most highly relevant and active areas of research for developing effective obesity treatments

Explore how GLP-1 therapies may reduce gout risk by lowering uric acid in patients with obesity and type 2 diabetes.

Being on GLP1 can feel like a relief and a curveball at the same time

Learn how GLP-1 weight loss programs may support heart health during American Heart Month

Women who used a GLP-1 within two years prior to becoming pregnant showed a higher risk